Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy - Takeaways - MDSpire

Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy

  • By

  • Haruko Takuwa

  • Shoko Sasaki

  • Naoki Goda

  • Megumi Takeuchi

  • May 20, 2026

Share

  • 1

    A 38-year-old woman with a BRCA1 variant was diagnosed with stage IIA breast cancer during her fifth pregnancy.

  • 2

    She underwent left total mastectomy at 18 weeks of gestation, followed by adjuvant chemotherapy after delivery.

  • 3

    The patient's family history included multiple cases of breast and ovarian cancer, highlighting her hereditary risk.

  • 4

    Risk-reducing salpingo-oophorectomy was performed after her pregnancy, with no malignant lesions found in the resected tissue.

  • 5

    Management of pregnancy-associated breast cancer should be individualized, considering safety and timing of interventions.

Original Source(s)

Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy

  • by Haruko Takuwa, Shoko Sasaki, Naoki Goda, Megumi Takeuchi

  • May 20, 2026

Related Content

Rethinking Progress in Clinical Trials

Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development

  • May 20, 2026

  • 11 min
Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min
This Week’s Biopharma News: FDA Commissioner Steps Down

Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.

  • May 19, 2026

  • 4 min